Walleye Capital’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$81.9K Buy
+600
New +$73.7K ﹤0.01% 4001
2025
Q4
Sell
-100
Closed -$13.4K 5023
2025
Q3
$13.4K Buy
+100
New +$12.1K ﹤0.01% 4257
2025
Q1
Sell
-8,000
Closed -$1.15M 4995
2024
Q4
$1.15M Buy
8,000
+5,200
+186% +$746K ﹤0.01% 2267
2024
Q3
$417K Buy
2,800
+600
+27% +$86K ﹤0.01% 3469
2024
Q2
$277K Buy
2,200
+400
+22% +$62.7K ﹤0.01% 4039
2024
Q1
$331K Sell
1,800
-100
-5% -$19K ﹤0.01% 3562
2023
Q4
$342K Sell
1,900
-6,400
-77% -$996K ﹤0.01% 3262
2023
Q3
$1.32M Buy
8,300
+4,800
+137% +$785K ﹤0.01% 2048
2023
Q2
$495K Buy
+3,500
New +$561K ﹤0.01% 2448
2020
Q1
Sell
-2,700
Closed -$250K 1524
2019
Q4
$250K Sell
2,700
-8,000
-75% -$672K 0.02% 1013
2019
Q3
$821K Sell
10,700
-9,400
-47% -$822K 0.05% 525
2019
Q2
$1.73M Buy
20,100
+19,900
+9,950% +$1.36M 0.19% 125
2019
Q1
$12K Buy
+200
New +$11.5K ﹤0.01% 1390

Other funds holding RGEN

Walleye Capital's RGEN Position: Q2 2026 in Review

Walleye Capital opened a new position in Repligen (RGEN) in Q2 2026: 1,707 shares worth $233K. The stake represents ﹤0.01% of the portfolio and ranks #3379 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RGEN as recently as Q4 2025.

Walleye Capital first reported a position in RGEN in Q2 2019 and has held it in 16 quarters since. The position peaked at $68.3M in Q4 2025. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • Walleye Capital held 1,707 shares of Repligen worth $233K as of Q2 2026.
  • Repligen was a new Walleye Capital position in Q2 2026.
  • Repligen made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3379 holding.
  • Walleye Capital first reported a position in Repligen in Q2 2019 and has held it in 16 quarters since.
  • Walleye Capital's Repligen position peaked at $68.3M in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.